Epgo23_normal: Expected probability to do third phase III trial

In Sterniii3/drugdevelopR: Utility-Based Optimal Phase II/III Drug Development Planning

Expected probability to do third phase III trial

Description

In the setting of Case 2: Strategy 2/2( + 1); at least two trials significant (and the treatment effect of the other one at least showing in the same direction) this function calculates the probability that a third phase III trial is necessary.

Usage

Epgo23_normal(kappa, n2, alpha, beta, a, b, w, Delta1, Delta2, in1, in2)

Arguments

kappa	threshold value for the go/no-go decision rule
n2	total sample size for phase II; must be even number
alpha	significance level
beta	1-beta power for calculation of sample size for phase III
a	lower boundary for the truncation
b	upper boundary for the truncation
w	weight for mixture prior distribution
Delta1	assumed true treatment effect for standardized difference in means
Delta2	assumed true treatment effect for standardized difference in means
in1	amount of information for Delta1 in terms of sample size
in2	amount of information for Delta2 in terms of sample size

Value

The output of the function Epgo23_normal() is the probability to a third phase III trial.

Examples

Epgo23_normal(kappa = 0.1, n2 = 50, w = 0.3, alpha = 0.025, beta = 0.1, a = 0.25, b=0.75,
                               Delta1 = 0.375, Delta2 = 0.625, in1 = 300, in2 = 600)

Sterniii3/drugdevelopR documentation built on Jan. 26, 2024, 6:17 a.m.